Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Relies On Fax Machine For Messages About Unreliable Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

“Know Your Source” campaign material will be sent to providers through same medium as offers from questionable wholesalers.

You may also be interested in...



Gray Market Investigation Could Push Track-and-Trace Debate

Rep. Cummings and Sen. Rockefeller suggest serialization is not an adequate replacement for state pedigree laws in letter to House and Senate leaders conferencing on user fee bills.

Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director

Nicole Verdun said children could participate in gene therapy clinical trials earlier if the necessary controls are in place.

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS077696

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel